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Abstract
FUS (fused in sarcoma) mislocalization and cytoplasmic aggregation are hallmark pathologies in FUS-related amyotrophic
lateral sclerosis and frontotemporal dementia. Many of the mechanistic hypotheses have focused on a loss of nuclear
function in the FUS-opathies, implicating dysregulated RNA transcription and splicing in driving neurodegeneration.
Recent studies describe an additional somato-dendritic localization for FUS in the cerebral cortex implying a regulatory
role in mRNA transport and local translation at the synapse. Here, we report that FUS is also abundant at the pre-synaptic
terminal of the neuromuscular junction (NMJ), suggesting an important function for this protein at peripheral synapses.
We have previously reported dose and age-dependent motor neuron degeneration in transgenic mice overexpressing human
wild-type FUS, resulting in a motor phenotype detected by 28 days and death by 100 days. Now, we report the earliest
structural events using electron microscopy and quantitative immunohistochemistry. Mitochondrial abnormalities in the
pre-synaptic motor nerve terminals are detected at postnatal day 6, which are more pronounced at P15 and accompanied by
a loss of synaptic vesicles and synaptophysin protein coupled with NMJs of a smaller size at a time when there is no detect-
able motor neuron loss. These changes occur in the presence of abundant FUS and support a peripheral toxic gain of function.
This appearance is typical of a ‘dying-back’ axonopathy, with the earliest manifestation being mitochondrial disruption.
These findings support our hypothesis that FUS has an important function at the NMJ, and challenge the ‘loss of nuclear
function’ hypothesis for disease pathogenesis in the FUS-opathies.
Received: August 1, 2017. Revised: November 23, 2017. Accepted: November 26, 2017
VC The Author(s) 2017. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
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Introduction
Amyotrophic lateral sclerosis (ALS) and frontotemporal demen-
tia (FTD) are fatal neurodegenerative diseases that share many
clinical, pathological and genetic features. Mutations in many
genes are implicated in the pathogenesis of both diseases,
including the gene encoding Fused in Sarcoma (FUS), which ac-
counts for 5% of familial ALS cases (1–3). FUS mutations oc-
cur predominantly in the C-terminal and disrupt the nuclear
localising signal (NLS) leading to cytoplasmic mislocalization
and aggregation of FUS protein (4,5). Cytoplasmic inclusions of
wild-type FUS protein also occur in 5% of FTD cases, when it
co-localises with the functionally similar proteins Ewing’s
Sarcoma (EWS) and TAF15 (6). This is in contrast to ALS-FUS
where mutant FUS aggregates occur in the absence of these
proteins (7). We have previously shown that transgenic mice
overexpressing human wild-type FUS develop cytoplasmic
aggregates of FUS in the brain and spinal cord, leading to
progressive hind limb paralysis and motor neuron degeneration
in an age and dose-dependent manner (8).
FUS is a predominantly nuclear protein involved in many
aspects of RNA processing (9). However, a growing body of
evidence now points towards a cytoplasmic role of FUS in the
transport, stability and local translation of mRNA at the synap-
ses. Studies in hippocampal neurons revealed that FUS associ-
ates with mRNA encoding an actin-stabilising protein Nd1-L
and facilitates its transport to dendritic spines (10–12). A study
in transgenic mice demonstrated that mutant FUS induces
motor neuron degeneration preceded by early abnormalities
at the neuromuscular junction (NMJ) through a toxic gain of
function (13). Another recent study reported that FUS knock-
down reduced synaptic transmission both in cultures and
in vivo, resulting in behavioural aberrations in FUS knockdown
mice (14). These studies appear to link impaired cytoplasmic
function of FUS to synaptic dysfunction and neurodegeneration.
In many neurodegenerative diseases, synaptic dysfunction
and disruption are some of the earliest pathological events that
occur long before neuronal loss. Accumulating evidence sug-
gests that degeneration of the NMJ is an early feature of ALS
and may contribute to motor neuron death (15–17). Recent stud-
ies in animal models and ALS patients suggest a progressive
distal to proximal ‘dying-back’ disease mechanism, implicating
neuromuscular synaptic vulnerability prior to clinical manifes-
tation (15,16,18,19). The vast majority of animal model studies
explore the effects of mutant SOD1 models, and relatively little
is known about disease mechanisms in mouse models of other
ALS-linked genes such as TDP-43 and FUS.
Here, we report that FUS is abundant at the pre-synaptic ter-
minal at the NMJ in non-transgenic mice implying that it plays
an important role in synaptic function. Mice over-expressing
human wild-type FUS develop significant loss of NMJs by
post-natal day 15, which precedes motor neuron loss and is as-
sociated with dramatic ultrastructural changes including mito-
chondrial vacuolation and a loss of synaptic vesicles. These
results indicate that FUS plays an important role at the NMJ,
and that overexpression of FUS leads to a ‘dying-back’ axonal
and subsequent motor neuron degeneration.
Results
FUS is abundant at the neuromuscular junctions
Immunohistochemistry revealed a perfect co-localization of
FUS with the NMJ marker a-bungarotoxin (BTX) in the
gastrocnemius muscle in NTg adult mice (Fig. 1A). Similar in-
vestigation of another ALS linked RNA binding protein, TDP-43,
showed no such localization to the NMJ (Fig. 1A) in NTg mice,
suggesting that FUS has a specific role at the NMJ that is distinct
from TDP-43. In order to identify whether FUS was localised to
the pre- or post-synaptic side of the NMJ, we performed super
resolution microscopy to compare the FUS and BTX staining
(Fig. 1B). We observed diffuse cytoplasmic FUS staining within
the nerve terminal surrounded by but not overlapping the BTX
stain. Given that the BTX stains post-synaptic acetylcholine re-
ceptors, this confirms that FUS is localised to the pre-synaptic
side of the NMJ.
We have previously shown that low level increases in FUS in
the hFUS (þ/) mice do not result in any motor impairment or
pathological FUS deposition (8), and here we show that these
animals also demonstrate no evidence of NMJ loss or pathology
by 8 weeks (P56) of age (Fig. 2A and B). In contrast, homozygous
hFUS (þ/þ) mice exhibit a degenerative motor phenotype that
necessitates culling by this age (8). Immunohistochemistry in
these end stage hFUS (þ/þ) mice demonstrates major changes
in NMJ morphology and peripheral denervation by P56 deter-
mined by the significant loss of co-localization between both
FUS and BTX [P< 0.001 vs NTg and hFUS (þ/) littermates] and
the pre-synaptic marker synaptophysin (SYP) and BTX [P< 0.001
vs NTg and hFUS (þ/)] littermates) in surviving NMJs (Fig. 2,
Supplementary Material, Fig. S1). Staining for neurofilament
medium chain (NFM145) confirms denervation of the NMJ in the
hFUS (þ/þ) end stage animals (S2).
Loss of pre-synaptic protein from neuromuscular
junctions at early pre-symptomatic stage P15 without
loss of spinal cord motor neurons
In order to investigate early disease events at the NMJ in these ani-
mals we performed immunohistochemistry on muscle sections
from pre-symptomatic animals. At early pre-symptomatic stage
P6, NMJs were fully innervated as indicated by co-localization of
BTX and SYP in NTg, hFUS (þ/) and hFUS (þ/þ) mice (Fig. 3A and
Supplementary Material, Fig. S3). In addition, FUS was abundant
at the terminals in these animals (Fig. 3B). However, a loss of pre-
synaptic protein SYP at the NMJs was observed in hFUS (þ/þ)
mice at a further pre-symptomatic stage P15 (Fig. 3C and
Supplementary Material, Fig. S3), with a significant decrease in the
number of NMJs with complete overlap between BTX and SYP
[P< 0.001; hFUS (þ/þ) vs NTg and hFUS (þ/)] and a significant in-
crease in NMJs with no evidence of BTX and SYP overlap
[P< 0.001; hFUS (þ/þ) vs NTg and hFUS (þ/)] (Fig. 3C and F).
Although the gross morphology of NMJs in NTg, hFUS (þ/) and
hFUS (þ/þ) mice at P6 was unchanged, by P15 there was a signifi-
cant difference in the average area of NMJs in hFUS (þ/þ) mice
[P¼ 0.004 vs NTg; P¼ 0.005 vs hFUS (þ/)] (Fig. 3E). Interestingly,
FUS was still abundant at the NMJs in hFUS (þ/þ) mice at P15
(Fig. 3D), suggesting that the loss of SYP in these mice is not sim-
ply a marker of the degenerating pre-synaptic terminal, but rather,
may reflect a specific aberrant FUS function and a loss of synaptic
vesicles due to an over abundance of FUS.
Despite the observed NMJ degneration in hFUS (þ/þ) mice at
pre-symptomatic stage P15, assessment of large a-motor neurons
in the ventral horn of the lumbar spinal cord revealed no signifi-
cant difference in the number of spinal cord motor neurons at P15
between NTg, hFUS (þ/) and hFUS (þ/þ) mice [NTg vs hFUS (þ/)
P¼ 0.99, NTg vs hFUS (þ/þ) P¼ 0.99, hFUS (þ/) vs hFUS (þ/þ)
P¼ 0.89] (Fig. 4A and B). Even at a later pre-symptomatic (P21)
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stage, there is no significant reduction in the number of motor
neurons in the hFUS (þ/þ) mice compared with their hemizygous
and NTg littermates [hFUS (þ/þ) vs hFUS (þ/) P¼ 0.63, hFUS (þ/þ)
vs NTg P¼ 0.19] (Fig. 4A and B). Interestingly, there is a significant
decline in motor neuron number from P15 to P56 in all mice [NTg
P¼ 0.009, hFUS (þ/) P¼ 0.002, hFUS (þ/þ) P< 0.001], regardless of
genotype, suggesting that some form of motor neuronal ‘pruning’
in the spinal cord is a normal developmental event. This pruning
appears to be slightly (although not significantly) enhanced in
transgenic vs NTg P21 animals [hFUS (þ/) vs NTg P¼ 0.08, hFUS
(þ/þ) vs NTg P¼ 0.10], which may indicate a role for FUS in this
process. However, in the hFUS (þ/þ) mice there was a much larger
decrease in motor neuron number by P56 compared with both NTg
and hFUS (þ/) animals [NTg vs hFUS (þ/þ) P< 0.001, hFUS (þ/)
vs hFUS (þ/þ) P¼ 0.004] (Fig. 4A and B), indicative of a pathological
loss of neurons in these animals that occurs after NMJ
degeneration.
Dramatic ultrastructural changes in the pre-synaptic
terminal of pre-symptomatic FUS (þ/þ) mice
In order to explore pre-symptomatic changes in the ultrastruc-
tural morphology at the NMJs we performed TEM in NTg and
hFUS (þ/þ) P15 mice. We observed an abundance of synaptic
vesicles and healthy mitochondria at the axon terminals in NTg
mice (Fig. 5A and B), however, we found a dramatic loss of syn-
aptic vesicles at nerve terminals of hFUS (þ/þ) mice which ap-
peared disrupted and fragmented, with multiple vacuoles and
empty spaces inside (Fig. 5C and D and Supplementary Material,
Fig. S4). On occasion, this was accompanied by the extension of
Schwann cell processes into the synaptic cleft to make contact
with the post-synaptic junctional folds, indicating complete
NMJ denervation (Fig. 5E and F). Quantification of mitochondria
at the pre-synaptic nerve terminals using the TEM images re-
vealed a significant decrease in the number in hFUS (þ/þ) mice
at P15 [P¼ 0.003 vs NTg; P¼ 0.008 vs hFUS (þ/); Fig. 7F] while
many of those that remained had pronounced abnormalities in-
cluding disorganised cristae and large vacuoles (Fig. 6A–D).
These ultrastructural changes are consistent with our immuno-
histochemical studies demonstrating the loss of synaptic pro-
tein SYP at the NMJs (Fig. 3C) and the significant decrease in the
average NMJ area in hFUS (þ/þ) mice at P15. As expected from
the immunohistochemistry data, the hFUS (þ/) mice showed
no major structural differences compared with the NTg animals
(Supplementary Material, Fig. S5). The mitochondrial abnormal-
ities we observed in our hFUS (þ/þ) mice are similar to those de-
scribed in the nerve terminals of aged rats (20), as well as SOD1
and TDP-43 transgenic mice (21–23). It is important to note that
despite the profound pre-synaptic mitochondrial abnormalities
observed in the hFUS (þ/þ) mice at P15, mitochondria in the
post-synaptic muscle endplate were abundant and of normal
Figure 1. FUS is abundant at the neuromuscular junction in non-transgenic mice. (A) FUS (green) is abundant and co-localised with BTX (red) whereas TDP-43 is absent
at the NMJ in adult NTg mice (scale bar: 20 lm). (B) Super resolution microscopy of the NMJ shows diffuse FUS (green) surrounded by BTX (red) demonstrating clear sep-
aration between the pre-synaptic (FUS) and post-synaptic (BTX) sides of the NMJ (scale bar: 10 lm).
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appearance (Figs 5 and 6). This is consistent with recent studies
demonstrating the vulnerability of axonal mitochondria and
showing that distal axon terminals undergo the earliest damage
in the course of patients with ALS (24–29). These robust patho-
logical changes in NMJ ultrastructure demonstrate that an
increase in cytoplasmic mislocalization of FUS in hFUS (þ/þ)
mice results in major synaptic disruption prior to symptom
onset or neuronal loss.
To further investigate the earliest aspects of this disruption,
we sought to analyse ultrastructural changes at the NMJ in P6
animals. At this age, the majority of the pre-synaptic terminals
in NTg, hFUS (þ/) and hFUS (þ/þ) mice were filled with synap-
tic vesicles and healthy mitochondria (Fig. 7). This is consistent
with our immunohistochemical study showing an abundance
of the pre-synaptic vesicle membrane protein SYP at the NMJs
in these animals (Fig. 3A). Quantification of these TEM images
suggests that P6 hFUS (þ/þ) mice have around 1/3 less mito-
chondria than their NTg littermates, although, this reduction
did not reach significance (P¼ 0.26, Fig. 7E). Consistent with this
finding however, we identified a number of mitochondrial ab-
normalities at the pre-synaptic terminals in a small number of
the NMJs in P6 hFUS (þ/þ) mice that were never observed in
NTg or hFUS (þ/) mice (Fig. 8). Some of the mitochondria pre-
sent showed vacuolation, an abnormal arrangement of cristae
and ‘onion-ring’ membranous structures (Fig. 8A, C, D respec-
tively). These are recognised features of mitochondrial degener-
ation and suggest that mitochondrial dysfunction may be one
of the prime drivers of FUS-linked disease.
Discussion
Many strands of evidence suggest that synaptic dysfunction
and disruption at the NMJ is one of the earliest events in ALS
and leads to muscle atrophy that is the hallmark of this disease
(15,16,18). Our understanding of the mechanisms driving NMJ
dysfunction largely come from studies on mutant SOD1 in
Figure 2. Homozygous hFUS (þ/þ) transgenic mice show a loss of NMJs by the end stage of disease. (A, C) Co-localization of BTX with FUS revealed an abundance of
FUS at the NMJs in P56 NTg and hFUS (þ/) transgenic mice whilst homozygous hFUS (þ/þ) mice, who have severe hind limb paralysis by this age, show a significant
decrease in FUS and BTX co-localization (**P<0.001) (scale bar 15 lm). (B, D) Synaptophysin (SYP) staining shows that the NMJ is retained in P56 mice from NTg and
hFUS (þ/) mice but that there is a significant loss of SYP and BTX co-localization in hFUS (þ/þ) animals by P56 (**P<0.001) (scale bar 15 lm). Significance was deter-
mined using a 2-way ANOVA with Holm-Sidak post hoc test.
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transgenic mice and TDP-43 and FUS toxicity in Drosophila and
zebrafish (16,19,30–35). Here, we report that in mice, endoge-
nous FUS is abundant at the NMJ and that overexpression of hu-
man wild-type FUS causes a progressive loss of NMJs. This was
evident at post-natal day 15, prior to the earliest motor pheno-
type of tremor and altered gait, which appears around P28 (8)
and before motor neuron loss in the spinal cord was detected.
NMJ loss was accompanied by striking ultrastructural changes
at the pre-synaptic terminals including the loss of synaptic vesi-
cles and a reduced number of mitochondria, with many of those
remaining having major structural abnormalities. More subtle
features of mitochondrial vacuolation and disordered cristae
and membranes were already present at post-natal day 6.
These findings indicate that FUS plays an important role in
synaptic function at the NMJ, and that FUS overexpression
causes mitochondrial disruption, NMJ loss and a ‘dying-back’
axonopathy, which eventually leads to motor neuron degenera-
tion. This sequence of events is similar to those observed in mu-
tant SOD1 and TDP-43 mediated NMJ degeneration (16,19,30,32)
and indeed central synaptic degeneration observed in
transgenic models of Alzheimer’s and Parkinson’s (36–38).
Interestingly FUS-related degeneration bears a striking similar-
ity to that seen in Spinal Muscular Atrophy (SMA). FUS and
SMN, the loss of which causes SMA, are both RNA-binding pro-
teins involved in similar cell processes including splicing. They
have been shown to interact with each other and SMN has been
found in cytoplasmic mutant-FUS aggregates (39,40). Indeed
studies using the same hFUS overexpressing mouse line re-
ported here have shown that there are changes in RNA splicing
and the spliceosome that are similar to those seen in SMN
mouse models (41). Further mouse models of both diseases
have now been shown to have degeneration of the NMJ as an
Figure 3. Neuromuscular junction degeneration at post-natal day 15 in hFUS (þ/þ) mice. (A,B) NMJs are fully innervated by SYP with abundant FUS in NTg, hFUS (þ/)
and hFUS (þ/þ) mice at post-natal day 6 (scale bar: 10 lm). (C,D) At post-natal day 15, a significant loss of SYP at the NMJs was found in hFUS (þ/þ) mice, however FUS
was still abundant (scale bar: 20 lm). (E) There was no significant difference in the average NMJ area between NTg, hFUS (þ/) and hFUS (þ/þ) mice at post-natal day 6,
but a significant difference in the average NMJ area was found in hFUS (þ/þ) mice at post-natal day 15 [*P¼0.004 vs NTg; *P¼0.005 vs hFUS (þ/)]. Average NMJ area in
P15 NTg and hFUS (þ/) mice was significantly increased compared with P6 NTg and hFUS (þ/) mice (**P< 0.001), but not in hFUS (þ/þ) mice (P¼0.316). (F) In P15 hFUS
(þ/þ) mice, there was a significant decrease in the number of NMJs with complete BTX and SYP overlap (**P<0.001), and a consummate significant increased number of
NMJs with no overlaps of BTX and SYP (*P<0.001). (N¼3–4 for all genotypes). Significance was determined using a 2-way ANOVA with a Holm-Sidak post hoc test.
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early disease event (42,43). Given the many links between FUS
and SMN, it is conceivable that the two diseases share a com-
mon pathomechanism.
Our observation that FUS is abundant at the NMJ emphasises
the important role that FUS plays outside the nucleus, particu-
larly in the transport of mRNA into axons and dendrites and the
regulation of local translation of synaptic proteins (11,44). FUS
has previously been observed in close proximity to synaptic vesi-
cles within the axon terminal of rat hippocampal neurons using
super-resolution microscopy (45). Furthermore, dysfunction and
disruption of cortical synaptic connections have previously been
reported following FUS knock-down and overexpression (14,44).
Here, however, we show that increasing FUS concentration by a
factor of 1.7 above endogenous (8) is sufficient to cause a devas-
tating effect in the peripheral nervous system at the NMJ.
In order to define the sequence of events that lead to motor
neuron degeneration, we performed immunohistochemical
studies on NMJs in pre-symptomatic animals in the gastrocne-
mius muscle and correlated this with motor neuron counts in
the lumbar spinal cord. A significant decrease in the average
surface area of NMJs was accompanied by a significant loss of
the pre-synaptic protein synaptophysin in hFUS (þ/þ) mice at
P15 that was not detectable at P6. Surprisingly, FUS protein was
still abundant at the pre-synaptic terminal in NMJs at P15, sug-
gesting that the loss of synaptophysin is not due to complete
nerve terminal loss, but rather that FUS overexpression may im-
pair synaptic protein translation. The association of FUS with
cytoplasmic stress granules suggests it may act as an active re-
pressor of translation (46,47), thus the overexpression of FUS
may directly repress translation of synaptophysin and other
pre-synaptic proteins in homozygous mice or aberrantly pro-
cess other mRNAs at the synaptic terminals, causing synaptic
defects by a toxic gain-of-function. Despite the observed NMJ
degeneration in hFUS (þ/þ) mice at P15, there was no significant
motor neuron loss in the lumbar spinal cord compared with
NTg and hFUS (þ/) mice at this stage. Interestingly, we
observed a reduction in motor neuron number in all mice, re-
gardless of genotype, from 15 to 56 days of age, suggesting that
there are post-natal developmental refinements of the rodent
motor system, whereby extraneous cells are removed.
Certainly, studies have shown there are critical post-natal
periods for the development of normal motor function in the ro-
dent (48). The subtle differences we observed in the profile of
motor neuron reduction over this time between the transgenic
and NTg animals, with both the hFUS (þ/) and hFUS (þ/þ) ani-
mals showing a greater reduction by P21, may suggest that FUS
has a role to play in this developmental process, and indeed,
this early change may be indicative of an increased susceptibil-
ity to disease in adulthood.
Although all animals displayed a reduction in motor neu-
rons between 15 and 56 days of age, this reduction was signifi-
cantly enhanced in a pathological fashion in the symptomatic
hFUS (þ/þ) mice, compared with the non-symptomatic NTg and
hFUS (þ/) animals, confirming that motor neuron degenera-
tion in these WT-overexpressing mice begins in the periphery
well before motor neuron loss is observed in the spinal cord.
This finding supports our hypothesis that the disease process
in these animals is a ‘dying-back’ axonopathy mechanism
similar to that reported in other ALS gene animal models and
some human data (15,16,19,32).
The vast majority of studies describing a ‘dying-back’ axon-
opathy mechanism in ALS are based on mutant SOD1 models
(15,16,19) and relatively little is known about disease mecha-
nisms for FUS-linked ALS and FTLD. Recent studies in Drosophila
and zebrafish indicate that loss and gain of toxic FUS function
may cause early defects in axonal transport, pre-synaptic struc-
ture and transmission at the NMJ preceding motor neuron de-
generation (31,33–35). Motor neuron degeneration preceded by
structural and functional changes at the NMJ has recently been
reported in FUS transgenic mice (13). Interestingly, a motor
neuron degeneration phenotype was only observed in mice ex-
pressing mutant FUS and not in the hemizygous or homozygous
mice expressing wild-type FUS, which indicated a mutant-
dependent toxicity. However, wild-type FUS accumulation has
been found in both FTLD and ALS patients, and studies in ro-
dents also demonstrated that increased expression of wild-type
FUS is pathogenic and causes neurodegeneration (8,49). Further,
there are reported cases of FUS mutations in the 3’UTR of
the gene that result in an increased protein expression that
mislocalises to the cytoplasm (50). This is further supported by
reports of wild-type FUS toxicity in other species (33,51,52).
Furthermore, in contrast to our mice, the mutant FUS express-
ing mice exhibited a slowly progressive phenotype, with
both pre- and post-synaptic deficits being reported (13). These
Figure 4. No significant loss of spinal cord motor neurons in hFUS (þ/þ) mice at
post-natal day 15 and day 21. (A) Cresyl violet staining of the large diameter
a-motor neurons in the ventral horn of the lumbar spinal cord in NTg, hFUS (þ/
) and hFUS (þ/þ) mice at P15, P21 and P56. (B) At P15, there was no significant
difference in the number of motor neurons between NTg, hFUS (þ/) and hFUS
(þ/þ) mice and hence no neuronal loss in hFUS (þ/þ) mice despite NMJ degener-
ation. At P21, there was a non-significant reduction in the number of motor
neurons in all three genotypes compared with P15 [NTg P¼0.78, hFUS (þ/)
P¼0.08, hFUS (þ/þ) P¼0.10], which reached significance by P56 [NTg P¼0.009,
hFUS (þ/) P¼ 0.002, hFUS (þ/þ) P<0.001]. In hFUS (þ/þ) mice there was a
significant loss of motor neurons compared with NTg and hFUS (þ/) mice at
the end-stage P56 [NTg vs hFUS (þ/þ) P< 0.001, hFUS (þ/) vs hFUS (þ/þ)
P¼0.004]. (N¼ 3–4 for all genotypes). Significance was determined using a
2-way ANOVA with a Holm-Sidak post hoc test.
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differences may be due to different promoter systems, expres-
sion levels and background strain variations in comparison
with our mice.
The earliest ultrastructural changes at the NMJ in hFUS (þ/þ)
mice were to mitochondria at the pre-synaptic nerve terminals.
These were subtle at P6, involving vacuolation and membrane
abnormalities, but were much more pronounced by P15 with a
significant loss of morphologically normal mitochondria and
synaptic vesicles. Interestingly, there is a trend towards a de-
crease in the number of mitochondria in hFUS (þ/) animals at
both P6 and P15 despite these animals being asymptomatic out
to 2 years of age. However, it should be noted that quantification
of the TEM images is only semi-quantitative and further investi-
gations will be needed to determine how significant this is for
disease. Mitochondrial dysfunction is increasingly recognised as
a converging point for many pathological pathways in ALS
(22,28,53–55), and has previously been described in ALS-FUS
patients and other disease models (54,56,57). A number of mito-
chondrial proteins have been identified as FUS interacting part-
ners (53) and FUS regulates the expression of several genes
involved in mitochondrial biogenesis, homeostasis and function
(58,59). Mitochondrial defects following FUS overexpression may
therefore be due to dysregulation of mitochondrial, synaptic or
cytoskeletal genes, but may also be due to direct toxicity of the
FUS protein to mitochondria. Identifying whether the overex-
pression of FUS causes the mitochondrial dysfunction and loss
of synaptic vesicles directly or whether these are simply symp-
toms of a sick motor neuron is a crucial next step in determining
early disease events. Whatever the mechanisms our results sup-
port the hypothesis that mitochondrial dysfunction and early
degeneration of the NMJ is a convergent event in the pathogene-
sis of ALS (26,28,29).
Materials and Methods
Ethics statement
Experiments were carried out under the UK Animals (Scientific
Procedures) Act 1986, and were approved by the Kings College,
London ethics review panel.
Transgenic mice
Transgenic animals were generated and genotyped as described
in Mitchell et al., 2013 (8), and were maintained on a C57Bl/6J
background for all experiments. Mice were housed in a 12 h: 12
Figure 5. Dramatic ultrastructural changes of the neuromuscular junctions in hFUS (þ/þ) mice at post-natal day 15. Ultrastructural analyses with TEM revealed dramatic
loss of synaptic vesicles and morphological abnormalities at the pre-synaptic nerve terminals in hFUS (þ/þ) mice, in contrast to NTg mice, in which the axon terminals
were full of healthy mitochondria and synaptic vesicles (A, B). Pre-synaptic nerve terminals in hFUS (þ/þ) mice were disrupted and fragmented (C, E, F), and sometimes
accompanied by the extension of Schwann cell processes into the synaptic cleft, in close contact with the junctional folds (E, F). Vacuoles and large empty spaces were
also found in some axon terminals (D). M, mitochondrion; V, synaptic vesicles; NT, nerve terminal; J, junctional folds; N, nucleus; SC, Schwann cell (scale bar: 500 nm).
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Figure 6. Neuromuscular junctions with striking mitochondrial abnormalities in hFUS (þ/þ) mice at post-natal day 15. High power TEM images illustrating striking mito-
chondrial abnormalities at the pre-synaptic terminals at P15, including a reduced mitochondrial density, disorganised cristae (A), vacuolation (arrows in B), swelling (C) and
absence of mitochondrial cristae (D). M, mitochondrion; V, synaptic vesicles; NT, nerve terminal; J, junctional folds; N, nucleus; SC, Schwann cell (scale bar: 500 nm).
Figure 7. Normal ultrastructural morphology of the majority of neuromuscular junctions in NTg, hFUS (þ/) and hFUS (þ/þ) mice at post-natal day 6. (A–D) TEM images
showing the pre-synaptic nerve terminals and post-synaptic muscle endplates of the NMJs. The majority of the pre-synaptic axon terminals contained an abundance
of synaptic vesicles and healthy mitochondria in NTg, hFUS (þ/) and hFUS (þ/þ) mice. M, mitochondrion; V, synaptic vesicles; NT, nerve terminal; J, junctional folds;
N, nucleus; SC, Schwann cell (scale bar: 500 nm). (E,F) Quantification of the number of mitochondria in the pre-synaptic nerve terminals from P6 and P15 mice shows a
significant reduction in the number of mitochondria in P15 hFUS (þ/þ) animals compare to NTg (*P¼0.003) and hFUS (þ/) animals (*P¼0.008, one-way ANOVA with a
Fisher LSD post hoc test).
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h light: dark cycle, with ad libitum access to food and water.
Homozygous animals were provided with wet mash from symp-
tom onset to help prolong survival.
Histology and immunohistochemistry
P21 and P56 homozygous FUS mice and their age-matched
hemizygous and non-transgenic littermates were anaesthetised
and perfused transcardially with phosphate buffer followed by
4% paraformaldehyde (PFA) in PBS. Brain, spinal cord and gas-
trocnemius muscles were dissected out and postfixed in 4% PFA
in 15% sucrose for 5 h, followed by cryoprotection in 30% su-
crose for 24 h. Brain and spinal cord were cut on a cryostat into
30 lm thick sections and muscles were cut into 40 lm thick sec-
tions. For post-natal day 6 and day 15 mice, brain, spinal cord
and gastrocnemius muscles were dissected and immersion-
fixed in 4% PFA overnight, then 4% PFA in 15% sucrose for 5 h,
cryoprotected in 30% sucrose for 24 h.
For Immunohistochemistry and the detection of NMJs, 40 lm
thick sections of gastrocnemius muscle were incubated in the
following antibodies: Alexa Fluor 555 a-bungarotoxin (1: 500, Life
Technologies), rabbit anti-Synaptophysin 1 (1: 500, Synaptic
Systems), rabbit anti-TDP-43 (1: 1000, Proteintech), rabbit anti-
FUS (1: 200, Sigma) and rabbit anti-Neurofilament M (145 kDa) (1:
150, Millipore). Tissues from three animals were taken for each
genotype [non-transgenic, hemizygous FUS (þ/) and homozy-
gous FUS (þ/þ)] at each age group. Muscle sections were then
washed and further incubated in donkey anti-rabbit IgG DyLight
488 secondary antibody (1: 500, Thermo Scientific) and imaged
with a Leica confocal microscope and LAS-AF software. To as-
sess the area of NMJs, total area stained by a-bungarotoxin was
measured in 30–40 NMJs per animal using ImageJ. To assess the
co-localization of pre- and post-synaptic membrane proteins at
the NMJ, 70–100 NMJs were analysed per animal per genotype for
all ages and full or partial co-localization of a-bungarotoxin and
synaptophysin or FUS and a-bungarotoxin were assessed by eye.
Super-resolution microscopy
Tissue was processed for normal immunohistochemistry and
then imaged and super-resolved images collected using a
Visitech-iSIM module coupled to a Nikon Ti-E microscope using
a Nikon 100x 1.49NA TIRF oil immersion lens. Green fluores-
cence was excited with a 488 nm laser and emission filtered
through a 525/25 filter. Red Fluorescence was excited with a 561
nm laser and emission filtered through a 630/30 filter. Multiple
images at focal planes were collected spaced apart by 0.05 mm.
Data were deconvolved using a Richardson-Lucy algorithm
specific to the iSIM mode of imaging to increase contrast and
resolution using the supplied Nikon deconvolution software.
Motor neuron count
Motor neuron counts in post-natal day 15, 21 and 56 mice were
performed in 3 or 4 animals per genotype. 4% PFA fixed lumbar
spinal cords were sectioned serially into 30 lm thick sections
and every sixth section was analysed. Sections were mounted
onto slides and left to air dry. To de-fat the sections, they were
incubated in 1: 1 ethanol/chloroform overnight. Sections were
stained in 0.1% cresyl violet at 37 C for 10 min, dehydrated,
mounted with DPX and sealed with coverslips. MetaMorph 7.7,
Molecular Devices, Wokingham, UK was used to count and com-
pare the number of spinal cord motor neurons. Large neurons
with diameter greater than 30 lm in the anterior horn of the
lumbar spinal cord were counted using the integrated mor-
phometry analysis package in 30 sections per animal.
Conventional electron microscopy
Gastrocnemius muscles were dissected from post-natal day 6
and day 15 mice, immersion-fixed in 4% PFA and 0.1% glutera-
dehyde in 0.1 M phosphate buffer (pH 7.3) overnight at 4 C. The
muscles were sliced into 150 lm thick sections with a vibratome
and stained with biotinylated a-BTX (1: 250) overnight at 4 C.
Sections were washed in 0.1 M phosphate buffer then incubated
in streptavidine-HRP for 10 min at room temperature, followed
Figure 8. Early mitochondrial abnormalities at the pre-synaptic nerve terminals in a small number of neuromuscular junctions in hFUS (þ/þ) mice at post-natal day 6.
Mitochondrial abnormalities were found at the axon terminals of the hFUS (þ/þ) mice in a small proportion of NMJs without apparent loss of synaptic vesicles.
Mitochondria were lost (B) or reduced in density, appeared darker in colour (C), with disorganised cristae (A) and ‘onion-ring’ membranes (D). M, mitochondrion; V, syn-
aptic vesicles; NT, nerve terminal; J, junctional folds; N, nucleus; SC, Schwann cell (scale bar: 500 nm).
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by DAB staining for 10 min. Regions of the samples with clusters
of NMJs were identified and micro-dissected into smaller frag-
ments under light microscope and processed for TEM.
Samples were washed in 0.1 M phosphate buffer and further
post-fixed in 1% osmium tetroxide in phosphate buffer at 4 C
for 1.5 h, then washed and dehydrated through a graded series
of ethanol, and then equilibrated with propylene oxide followed
by infiltration with epoxy resin (TAAB Laboratories Equipment,
Reading, UK). Samples were cut into smaller pieces prior to em-
bedding in epoxy resin and the embedded samples were left in
an oven to polymerize at 70 C for 24 h. Ultrathin sections
around 70–90 nm were cut using the ultramicrotome (Reichert-
Jung Ultracut E, Leica) and mounted on 150 mesh copper grids.
Grids were then stained with uranyl acetate and lead citrate to
enhance the contrast. The FEI Tecnai 12 transmission micro-
scope was used for sample imaging and images were captured
using an AMT 16000M camera.
Mitochondria count
The number of mitochondria in the pre-synaptic nerve terminal
was counted with the TEM images of the NMJs. On average
10 NMJs were assessed for mitochondria count in each animal
and 2–3 animals per genotype at post-natal day 6 and 15 were
assessed.
Statistical analyses
The data are presented as mean6 standard error of the mean
(SEM). A P value of<0.001 is considered to be highly significant,
and P value of<0.05 significant. Statistical significance was deter-
mined using either one-way or two-way analysis of variance
(ANOVA), followed by either a post hoc Holm-Sidak test (Fig. 1), a
post hoc Tukey test (Figs 2 and 3) or a Fisher LSD post hoc test (Fig. 6).
Supplementary Material
Supplementary Material is available at HMG online.
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